ABSTRACT To determine the value of specific immunotherapy with adjuvant BCG in operable lung cancer, the immunological and clinical results of serial postoperative injections of autologous irradiated tumour cells and BCG were compared with those of a single preoperative injection of BCG in two randomly selected groups of patients undergoing resection of their tumours. There was a significant rise in tuberculin skin reactivity from seven weeks to 11 months after operation in the treated group. Actuarial curves for survival and freedom from tumour recurrence and median survival times showed an advantage for the treated patients who had stage I tumours, but these differences were significant only at the levels p = 0-07-0-09. Survival and duration of freedom from tumour recurrence was greater in autograft-treated patients whose skin responded to a weak test dose of dinitrochlorobenzene (DNCB) after sensitisation with 2% DNCB than in control DNCB-positive patients (p 0.02). There were no significant differences in the actual proportion of patients from each group surviving at two years. The results show that this form of specific immunotherapy with adjuvant may have a beneficiat effect in patients with stage I tumours and those who become sensitised to 2% DNCB after the first exposure.
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Many investigations of immunotherapy in lung cancer have shown that it has at the most a weak therapeutic action. It is thus likely to be of value only where the tumour cell population has been reduced to a minimum, as after surgical resection. ' 
Methods
The preparation of the suspension of lung tumour cells and the laboratory tests of immunological function were described in a previous paper.5 The scheme of the project is set out in figure 1.
IMMUNOTHERAPY
Informed consent was obtained from patients undergoing thoracotomy for suspected lung cancer at two Glasgow hospitals over three years from August 1976. One week before operation they were given a single preoperative treatment with percutaneous BCG Glaxo (50-250 x 106 organisms per ml) to the deltoid region of the arm.4 The BCG was injected at five sites with a 20-needle Heaf gun adjusted to penetrate to a depth of 1 mm. Once the tumour was found at operation to be resectable, the patient was randomly allocated to the autograft or the control group. A cell suspension was prepared from the tumour of each patient in the autograft group. This was irradiated and divided into aliquots of approximately 3 ml. Provided that the diagnosis was confirmed by examination of the frozen section 3 ml of the cell suspension were injected intrader- At three weeks the mean increase in DNCB index of both groups was 0-5; at 7 weeks, it was 1-0 in the autograft group and 1-7 in the control group. The difference between the two groups was not significant. There was a significant rise in total white blood cells and a fall in T lymphocytes during the first three weeks after operation in the autograft group 3) . Similar changes were seen in the control group except that the fall in circulating T cell levels after operation was not significant. Although the overall pattern of change in median lymphocyte reactivity to PHA, PWM, and PPD was that of depression during the first five months after operation followed by recovery, the variation in results at any one time was so. large that these changes did not reach acceptable levels of statistical significance. There was no difference in median values between the two groups at any one time.
CLINICAL
From table 1 it can be seen that there was no significant difference between the clinical, surgical, or pathological features of the groups except for a higher proportion of pneumonectomies and largecell carcinomas in the autograft group. There was no significant difference in the actuarial curves for survival and freedom from tumour recurrence when all patients in both groups were compared. Patients with stage I tumours in the autograft group, however, fared better than controls in both respects, the significance of the difference between the curves being p = 0-09 (fig 4) . This difference appeared at six months, was maximal at 18 months, and decreased thereafter. Similar differences were seen when median times for survival and freedom from tumour recurrence were calculated (table 2) . Although a higher proportion of autograft patients were alive and free from tumour recurrence two years after operation, the difference was not significant (table 3) . The clinical results were assessed in relation to the preoperative immunological tests. A significant finding was that autograft patients who had a positive skin reaction to DNCB before the operation survived and remained free from tumour recurrence longer than control DNCB-positive patients (p = 002) ( fig 5) and longer also than control DNCBnegative patients (p = 0-04). There was no evidence that specific immunotherapy with BCG adjuvant decreased the ratio of distant metastases to local recurrences (table 4) .
Percutaneous BCG produced five raised erythematous discs in the deltoid region. These lesions became maximal at three weeks ( fig 6) . They became itchy but were never painful or ulcerated. They faded, leaving a barely visible scar, after six months. There was no case of a tumour developing at the site of injection and no macroscopic evidence of local infection. That this host defence depends on specific adaptive mechanisms in which host lymphocytes play a part is suggested by the better prognosis of patients with positive reactions to delayed hypersensitivity skin tests and laboratory evidence of active cellmediated immunity. Tumour-associated antigens and antibodies and immune complexes have been found in association with lung cancer." Stimulation of this defence mechanism has the theoretical advantage over adjuvant radiotherapy and chemotherapy that the activated lymphocytes and macrophages are able to locate and destroy tumour cell masses long before these become clinically obvious or detectable by scanning techniques.
The aim of adjuvant immunotherapy is to enhance the efforts of the host defence mechanism to eliminate residual tumour cells. BCG or Corynebacterium parvum are used to produce a general stimulation of lymphocytes and macrophages in the hope that their increased immunological activity will damage any "foreign" tumour cells that happen to be present. The longterm results of non-specific immunotherapy in lung cancer have, however, been disappointing. We have therefore sought to focus this cellular immunological reaction on to the residual tumour by injecting irradiated autologous tumour cells.
Use of autologous cells has the advantage that they are not destroyed by ordinary transplantation rejection mechanisms and so may have more time and opportunity to evoke an immunological attack on tumour cells left at operation. Other authors have reported beneficial results from injecting allogeneic lung cancer cells '2 and extracts'3 14 with adjuvant. These authors, however, failed to show that their treatment had produced any immunological effect. In our study a significant increase in tuberculin skin reaction was produced from seven weeks to 11 months after operation. Moreover, the normal postoperative depression of T cell count was partly abolished in the autograft group. The lack of more specific tests of cytotoxicity against tumour cells has, however, been a weakness of this and most other trials of immunotherapy.
In our study actuarial curves and median times for survival and freedom from tumour recurrence did show that autograft patients with stage I tumours fared better. The significance of the differences in the clinical results between the two groups was, however, relatively low (p = 0 07-0 09). This finding was similar to that of two other groups,'214 but the significance was less than in a third series. '3 The results suggest that, while the overall therapeutic effect of specific immunotherapy is relatively weak, there may be a subgroup within the stage I group of patients who are capable of benefiting from this treatment.
In view of the promising initial results and lack of side effects, further trials of specific immunotherapy should be considered. In these the treatment should be given over a long period. As the volume of tumour cells is necessarily limited, allogeneic cells or extracts would have to be used. More specific in vitro tests of the ability of macrophages and lymphocytes to kill tumour cells would also be highly desirable to show that benefit derived from the treatment was due to its effects on cell-mediated immunity. 
